Labcorp Holdings Inc.

The filings in this data set support a narrower reading than a full analysis would. Three things are on file: annual revenue for 2018 through 2025, a 10-K risk-factor excerpt dated 2026-02-24, and a 10-Q MD&A excerpt for the period ended 2026-03-31. No forensic scores are on file, so this synthesis gives no Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index value and does not characterize any of them. Revenue is the one quantitative thread available. Revenue fell from $16.12 billion in 2021 to $14.88 billion in 2022 and then to $12.16 billion in 2023, a combined decline of about 24.6% over two years. Revenue then rose to $13.01 billion in 2024 and $13.95 billion in 2025. The filings define a June 2023 spin-off of Fortrea Holdings Inc., and the excerpts do not say whether the historical revenue figures are restated for that separation. Readers may want to check how the company presents the 2023 comparison before treating that swing as operating performance. The 10-K risk factors name PAMA, CLIA, cGMP, the Animal Welfare Act, the Foreign Corrupt Practices Act, and cybersecurity and artificial intelligence tool risks, and the forward-looking statements list litigation and anti-fraud enforcement. These items are named but not quantified in the excerpts. A careful reader would separate what the company says could happen from what the reported numbers show, and here the numbers available are limited to revenue.

Catalyst.The provided data does not include the MD&A results discussion, so the drivers management cites for current performance are not visible here. The 10-Q MD&A excerpt for the period ended 2026-03-31 (filed 2026-05-04) contains only the forward-looking statements section, which lists factors such as PAMA reimbursement changes, price competition and price transparency, payer mix shifts, and acquisition integration. The annual revenue series shows $13.95 billion in 2025 against $13.01 billion in 2024, a rise of 7.2%, after growth of about 7.0% in 2024 from $12.16 billion in 2023.

Hidden risk.The most material tension a casual reader could miss is how much of the revenue base depends on payer and reimbursement rules that the filings flag repeatedly. Risk factor items 1 and 13 cite changes in government and third-party payer reimbursement and payer mix, and item 35 cites days sales outstanding, cash collections, and rising patient payment responsibility. Item 37 cites failure to keep an investment grade rating or to meet leverage covenants under the revolving credit facility. The data set includes no balance sheet or cash flow statements, so these exposures cannot be measured here.